Want to see HK:6998 full AI Analyst Report?
Top Page
Genor Biopharma Holdings Limited
(6998)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$2.00
▼(-34.64% Downside)
Action:Reiterated
Date:08/21/26
The score is led by a strong 2025 financial inflection and attractive earnings valuation (low P/E), but it is held back by weak technical momentum (below key moving averages with negative MACD) and the need to prove durability after prior years of volatile/weak revenue and a sharp rise in debt.
Positive Factors
2025 Profitability Inflection
The sharp 2025 move to meaningful revenue and profitability shows that the company can convert its biologics platform into commercial earnings. If maintained, the improved margin profile can support reinvestment in development, manufacturing, and market expansion over the next several quarters.
Negative Factors
Earnings Durability Risk
The 2025 earnings step-up follows a highly inconsistent operating history, including several loss-making years and periods without reported revenue. This makes it difficult to establish a dependable recurring base and increases the risk that future results remain uneven as products and licensing income develop.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Profitability Inflection
The sharp 2025 move to meaningful revenue and profitability shows that the company can convert its biologics platform into commercial earnings. If maintained, the improved margin profile can support reinvestment in development, manufacturing, and market expansion over the next several quarters.
Read all positive factors
Genor Biopharma Holdings Limited (6998) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.51B
Dividend YieldN/A
Average Volume (3M)653.65K
Price to Earnings (P/E)4.7
Beta (1Y)0.37
Revenue Growth1417.68%
EPS Growth660.14%
CountryHK
Employees1,545
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)0.24
Shares Outstanding2,014,041,700
10 Day Avg. Volume444,900
30 Day Avg. Volume653,650
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.17
Price to Sales (P/S)1.67
P/FCF Ratio11.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genor Biopharma Holdings Limited Business Overview & Revenue Model
Company Description
Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally....
How the Company Makes Money
Genor Biopharma primarily makes money through (1) sales of biologic drugs it commercializes (where revenue is recognized from product sales to distributors, hospitals, or other customers), and (2) out-licensing/licensing arrangements for its drug ...
Genor Biopharma Holdings Limited Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
63
Positive
Cash Flow
56
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.70B | 2.76B | 0.00 | 18.53M | 0.00 |
| Gross Profit | 1.76B | 1.78B | -84.96M | -45.04M | -73.21M |
| EBITDA | 954.29M | 924.14M | -686.81M | -851.84M | -1.03B |
| Net Income | 433.01M | 420.56M | -745.17M | -849.15M | -1.04B |
Balance Sheet | |||||
| Total Assets | 6.61B | 1.29B | 1.45B | 2.12B | 2.86B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 1.06B | 1.17B | 1.59B | 2.20B |
| Total Debt | 1.49B | 911.00K | 7.16M | 28.59M | 57.41M |
| Total Liabilities | 2.75B | 138.05M | 256.18M | 309.87M | 369.73M |
| Stockholders Equity | 3.86B | 1.15B | 1.19B | 1.80B | 2.49B |
Cash Flow | |||||
| Free Cash Flow | 404.05M | -123.55M | -426.15M | -590.56M | -695.13M |
| Operating Cash Flow | 451.73M | -121.98M | -425.12M | -577.61M | -623.74M |
| Investing Cash Flow | 1.24B | 8.01M | 5.99M | -12.94M | -54.26M |
| Financing Cash Flow | -744.78M | -1.56M | -6.82M | -57.39M | 17.57M |
Genor Biopharma Holdings Limited Technical Analysis
Positive
3.06
Price Trends
1.73
Positive
2.02
Negative
2.48
Negative
Market Momentum
<0.01
Negative
56.04
Neutral
96.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6998, the sentiment is Positive. The current price of 3.06 is above the 20-day moving average (MA) of 1.62, above the 50-day MA of 1.73, and above the 200-day MA of 2.48, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.04 is Neutral, neither overbought nor oversold. The STOCH value of 96.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6998.
Genor Biopharma Holdings Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$3.51B | 4.73 | 10.99% | ― | 1417.68% | 660.14% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$4.77B | 7.59 | 47.76% | ― | 286.20% | ― | |
50 Neutral | HK$1.86B | 18.12 | 48.25% | ― | 88.38% | ― | |
48 Neutral | HK$2.19B | 35.65 | 6.51% | ― | 605.95% | ― | |
47 Neutral | HK$2.81B | -5.16 | -32.32% | ― | 28.93% | 27.27% | |
46 Neutral | HK$1.49B | -7.09 | -41.81% | ― | ― | -4.24% |
* General Sector Average
HK:6998
Genor Biopharma Holdings Limited
1.70
-2.74
-61.71%
HK:6996
Antengene Corporation Limited
3.34
-3.84
-53.48%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
5.78
-5.59
-49.16%
HK:2181
Mabpharm Limited
0.44
-0.37
-45.63%
HK:3681
SinoMab Bioscience Ltd.
1.10
-0.68
-38.20%
HK:1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
3.21
-9.05
-73.84%
Genor Biopharma Holdings Limited Corporate Events
Edding Genor Chairman to Boost Stake as Company Launches Share Buyback
Aug 31, 2026
Edding Genor Group Holdings Limited has announced that chairman and chief executive officer Ni Xin will personally purchase additional shares in the company on the open market, investing up to USD1,000,000 starting 31 August 2026, subject to regul...
Edding Genor Posts Solid Interim Revenue as It Deepens Push Into Breast Cancer Therapies
Aug 28, 2026
Edding Genor reported interim results for the six months to 30 June 2026, its first full period after a strategic merger, posting revenue of RMB872.7 million, an adjusted EBITDA of RMB204.8 million, and a narrowed net loss of RMB65.9 million, supp...
Edding Genor Warns of First‑Half Loss as Drug Procurement Hits Sales
Aug 21, 2026
Edding Genor Group Holdings has warned that it expects first‑half 2026 revenue to fall to about RMB850 million to RMB900 million from RMB1.14 billion a year earlier, and to swing to a net loss of RMB60 million to RMB70 million from a RMB114....
Edding Genor Sets Board Meeting to Review Interim Results and Dividend Plan
Aug 18, 2026
Edding Genor Group Holdings Limited has scheduled a board meeting for 28 August 2026 to review and approve interim results for the six months ended 30 June 2026. The board will also consider the publication of these results, which will provide inv...
Edding Genor Advances GB268 Breast Cancer Trial with First Patient Dosed
Aug 6, 2026
Edding Genor Group Holdings Limited has reported the successful first dosing of a subject in its Phase Ib/II clinical trial of GB268, a PD-1/CTLA-4/VEGF trispecific antibody for locally advanced unresectable or metastatic breast cancer, including ...
Edding Genor’s Jing Zhu Da Sub-Licensing Deal Collapses After Upstream License Termination
Aug 5, 2026
Edding Genor Group Holdings Limited has disclosed that its 2023 sub-license agreement for the oncology drug Jing Zhu Da in Mainland China can no longer be performed after Syndax Pharmaceuticals terminated an original 2013 license held by EOC Pharm...
Edding Genor Realises US$48.4 Million from Sale of Candid Stake After UCB Takeover
Jul 16, 2026
Edding Genor Group Holdings has disclosed the disposal of its entire 2.29% equity stake in Candid Therapeutics following Candid’s acquisition by Belgian drugmaker UCB, receiving US$48.4 million as part of the cash consideration. The transact...
Edding Genor Launches Up to 10% Share Buyback Ahead of 2027 AGM
Jul 7, 2026
Edding Genor Group Holdings Limited has announced that its board will exercise a shareholder-approved mandate to repurchase up to 10% of the company’s issued shares on the open market before the 2027 annual general meeting. The repurchased s...
Edding Genor Wins NMPA Nod for Phase Ib/II Trial of Trispecific Breast Cancer Antibody GB268
Jul 2, 2026
Edding Genor Group Holdings Limited has secured approval from China’s National Medical Products Administration for an Investigational New Drug application to conduct a Phase Ib/II clinical trial of GB268 in locally advanced unresectable or m...
Edding Genor shareholders back board, accounts and 10% buyback mandate at AGM
Jun 26, 2026
Edding Genor Group Holdings Limited reported that all resolutions at its 26 June 2026 annual general meeting in Shanghai were approved by poll, with 1,990,748,274 shares eligible to vote after excluding treasury stock. The meeting, chaired by chai...
Edding Genor Chair to Boost Shareholding in USD1 Million Plan
Jun 10, 2026
Edding Genor Group Holdings Limited has announced that its chairman, executive director and chief executive officer, Ni Xin, plans to increase his stake in the company through open-market share purchases funded with his personal capital. The plann...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.